Answers are grounded in this paper and cite their sources.
Thirty years after the initial strategies to develop genetically engineered pigs for use as organ donors in xenotransplantation were described, evaluation of these pig organs in humans has begun.1 The initial experience includes decedent experiments in kidneys and hearts, as well as 5 clinical cases (2 hearts, 2 kidneys, and 1 auxiliary liver). The cardiac xenograft survival was 47 and 40 d, whereas patient survival was 60 and 40 d.2-4 In the initial kidney xenografts, patient survival was 52 d for the first kidney, and the second kidney was removed at 47 d with the patient still alive in the intensive care unit. The initial results in the decedent work as well as the clinical cases indicate that the initial barrier of hyperacute rejection (HAR) has been averted with genetic engineering, but that much work remains before we can begin to offer xenotransplantation as a routine therapy for the treatment of end-stage organ failure. Evaluation of the renal xenografts in decedents and the 2 cardiac xenografts make it clear that although HAR is no longer an issue the problem of antibody-mediated rejection (AMR) secondary to xenoantigens on the pig cell remains.5,6 Moving forward, 4 key areas that must be addressed to realize the goals of bringing xenotransplantation to clinical practice are (1) patient selection, (2) donor pig genetics, (3) immunosuppression issues, and (4) animal husbandry challenges. PATIENT SELECTION A key component of allotransplantation was the development of the paradigm where recipients were selected who had no preformed donor-specific antibody (DSA). Initial evaluation of patients for antipig DSA against triple knockout (TKO) pig cells suggested that as many as 30% of patients had no detectable antibody.7 Taken conservatively, it could mean that there is no DSA, or alternatively, we are just unable to identify antibody in those patients. Our unpublished results suggest that like allotransplantation in the 1960s and 1970s, initial histocompatibility testing was sufficient to detect high-level DSA and prevent HAR, but insufficient to pick up lower levels of DSA that would lead to early graft failure (<6 mo).8 Loupy et al5 showed in their evaluation of 2 GGTA1 knock out (KO)/thymokidney xenografts that clear signs of AMR were present at 56 h postreperfusion that occurred before any signs of graft dysfunction. Mohiuddin et al’s6 initial case using a cardiac xenograft from a pig that had 4 knockouts (GGTA1/β4GalNt2/CMAH/GHr) and 6 human transgenes (CD46/CD55/TBM/EPCR/HO-1/CD47) showed clear signs of AMR/injury. Moving forward, the development of sensitive and accurate detection methods for the presence of antipig DSA is going to be a prerequisite to successful xenotransplantation.7,9 The initial cardiac case was further complicated using IVIg for the treatment of hypogammglobulinemia. IVIg has subsequently been shown to contain significant antipig DSA and has the potential to cause significant graft injury. The influence of particular medical conditions and considerations surrounding informed consent and patient’s rights following entry into a clinical trial are important but not addressed in this discussion. These 2 topics are well covered by others.10,11 DONOR SELECTION/PIG GENETICS Thus far, there have been 2 approaches evaluated in human decedents or on clinical cases. (1) The GGTA1 KO thymokidneys and (2) the TKO (± GH receptor knockout) with multiple human transgenes designed to downregulate complement activation, thrombosis, and less specific cellular immune activities.2-4,12 The pathobiology of rejection was similar in the GGTA1 KO thymokidney versus the TKO with multiple transgenes, suggesting that the pathobiology of xenograft rejection was impacted more by the presence of xenoantigens and less by the addition of human transgenes.5,6 It is important to note that the transplanted heart had doubled in weight in 60 d, despite the presence of the GH KO phenotype of the donor pig.6 The possibility that rejection and not aberrant growth of the donor heart is the cause of the increase in size must be considered based upon this experience. It is possible that current pigs are not sufficient to provide routine long-term graft survival in clinical xenotransplantation, and although HAR is avoided using the current pigs, the antibody barrier is still the main issue with regard to moving into clinical trials. The need to further reduce xenoantigenicity in donor pigs through genetic engineering has been suggested and has been very fruitful in improving the pretransplant crossmatch to move xenotransplantation to the point of clinical consideration.7 IMMUNOSUPPRESSION The initial cardiac experience utilizing a protocol with T-cell and B-cell clinical induction immunosuppression was scaled back from the preclinical protocol in that 4 mg/kg rATG rather than 10 mg/kg, and only a single dose of rituximab was used in lieu of 2. The xenograft function in the initial patient was adequate until postoperative day 49 when the patient became hypotensive and required reinitiation of ECMO for terminal graft failure. Mycophenolic acid was stopped at day 22 for leukopenia and replaced with tacrolimus. Because the patient had problems with AMR, the most common cause of early graft failure in the preclinical model, it seems likely that moving forward it will be important to select patients who can tolerate similar immunosuppression to that used in the preclinical models, and then stick closely to the script outlined in the successful preclinical scenario. Significant debate remains regarding the ideal immunosuppressive regimen. An ideal regimen would include only drugs that transplant physicians/surgeons have experience using in the clinic. Tacrolimus-based regimens have been unsuccessful in prolonging renal xenograft survival in preclinical models of renal xenotransplantation.13 Recently, a regimen using all Food and Drug Administration-approved drugs that included costimulatory blockade with CTLA4-Ig, tacrolimus, mycophenolic acid, and sirolimus (started on postoperative day 42)-based regimen has allowed survival in a single animal of 280 d. This result is encouraging, but it is important to note that the xenografted kidney demonstrated significant chronic AMR manifesting as glomerulopathy, as well as cellular rejection.14 This protocol will require further experimentation before it can be considered as the baseline immunosuppression for clinical trials. The human decedent and clinical xenotransplantation experience was either too brief in duration (62 d maximum still in the 100-d window where AMR occurs in preclinical models) or complicated by suboptimal dosing to make definitive statements regarding which immunosuprression is optimal for a clinical trial. This leaves costimulation blockade-based regimens developed in preclinical nonhuman primate (NHP) models as the choice with the most compelling case for inclusion in clinical trials. Blockade of the CD40/CD154 pathway is more effective at prolonging survival than the CD28/CD80–CD86 pathway.15 The best results in preclinical renal transplant models have been using an anticomplement agent, T-cell depletion, B-cell depletion, and either anti-CD154 or anti-CD40 antibodies with mycophenolic acid and steroids. These regimens have produced >1-y survival in >60% of recipients with the longest survival approaching 5 y13 (Adams, personal communication). The inclusion of tacrolimus and sirolimus in CD40/CD154 costimulation blockade-based immunosuppression regimens has resulted in significant infectious complications that have not been encountered in regimens that have not used these reagents.13,14,16 It is also possible that the creation of new pigs with fewer xenoantigens will reduce the antibody barrier to the point where tacrolimus-based immunosuppressive regimens may become effective in patients in the absence of costimulation blockade. PIG HOUSING ANIMAL HUSBANDRY ISSUES The xenotransplantation community along with the regulatory authorities have established guidelines regard the production of pigs who will be devoid of pathogens that could put both the patient and public which might cause zoonotic disease in humans. The production of such pigs requires sophisticated dedicated housing and the development of robust pathogen testing.17 In addition, some pathogens, especially porcine cytomegalovirus (pCMV), has been associated with early graft loss.18 The exclusion of pCMV is simple if special precautions are taken in delivering and rearing the source pigs. Thus far, published work in clinical human xenotransplantation and in decedent experiments has not utilized pigs from barrier facilities, and pathogen testing has been relatively simple. The result of the lack of high-end clinical animal rearing and testing has several important implications, the initial manifestation presented in the first clinical cardiac case where the recipient tested positive for pCMV 20 d post transplantation.4 Because the pig did not come from a clinical grade barrier facility, and testing was simple polymerase chain reaction, and not digital droplet polymerase chain reaction, there is the very significant question of whether pCMV contributed to cardiac xenograft dysfunction. pCMV is a confounding variable that should be very easy to correct if appropriate clinical grade housing and testing are employed.17 The absence of appropriate pig housing and pathogen testing will create additional problems for xenotransplantation with regard to public perception and ultimately regulatory oversight. If we are perceived to be cutting corners or ignoring well established concerns, then it will be very difficult to garner the necessary support to overcome missteps. It is going to be important to transition to barrier facilities and taking advantage of sophisticated well thought out pathogen testing in the immediate future for both decedent and clinical work in humans. PATH FORWARD Clinical experience and data from preclinical models suggest that great progress has been made regarding the development of donor pigs for use in humans, but that there is still too much early graft loss from AMR to surge ahead with clinical efforts.19 Like data from the preclinical model, the human experience shows that transgenes have not overcome the AMR barrier.13,20 The following steps (Figure 1) are likely to be required before successful clinical xenotransplantation can be achieved:Figure 1.: Path to clinical xenotransplantation. The development of a new pig with a better crossmatch in patients will require (A) additional genetic engineering followed by testing in a preclinical nonhuman primate model that will include identification of an immunosuppressive regimen that can be used in clinical trials (B). The development of more detailed histocompatibility testing will facilitate the identification of the most appropriate initial recipients to ensure clinical success (C). Created with Biorender.com. A new pig with fewer xenoantigens will likely be necessary to improve the pretransplant crossmatch and achieve more consistent success free from early AMR. Testing of the new pig in an NHP preclinical model. This point will be argued, but it is hard to imagine being able to get enough data in decedents quickly and for a long enough posttransplant period (likely 100 d in the decedent) to replace the NHP model.21 It should also be pointed out that the NHP model has thus far been very predictive of the clinical scenario with regard to AMR being the most proximal barrier, and the failure of transgenes to overcome this issue.22 Improved histocompatibility testing must be developed to enable programs to choose those patients most likely to receive benefit from a xenograft without the threat of early AMR.23,24 Simply reverting to circa 1975 complement dependent cytotoxicity crossmatching will guarantee clinical failures. Glycan (blood group) crossmatching is less defined and thus more complicated than for allotransplantation, and the development of specific glycan and swine leukocyte antigen reagents is going to be critical to reduce early graft failures encountered because of AMR. The use of T- and B-cell crossmatching to distinguish class II from class I DSA is one example where simply applying allograft crossmatching to xenotransplantation will not be feasible in the pig because nearly 50% of pig T cells have class II swine leukocyte antigen. Initially, histocompatibility testing for xenotransplantation will be more difficult than allotransplantation because there will be few retrospective cases to analyze and determine what test result discriminates success versus failure. It is critical to remember that xenotransplantation represents experimental rather than clinical medicine, and so at this point, data are much more likely to guide successful trials rather than opinion. Data from preclinical models can clarify early promising results in the decedent models. The use of complement inhibition and tacrolimus is an example where at 1-wk renal xenograft performance is promising in both models, but at 16–62 d all grafts succumb to AMR in the preclinical model.13,25 The human experience suggests that clinical xenotransplantation will work sooner rather than later, but there is still some heavy lifting in front of us that will require continued careful detailed laboratory investigation guided by the feedback from preclinical evaluation.
No takes yet. Share an insight, caveat, or question.
A. Joseph Tector (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: